质量水平
方案
≥98%
表单
powder
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
2-8°C
SMILES字符串
C1(SC(N2CCC(NC=N3)=C3C2)=N4)=C4C=CC=C1
生化/生理作用
Restores ATG9A function and modulates intracellular trafficking and autophagy.
BCH-HSP-C01, a novel pharmacotherapeutic agent, is engineered to rectify ATG9A-related pathologies. Its primary mode of action entails the regulation of intracellular trafficking mechanisms, with a pronounced effect on the RAB protein family, integral to vesicular transport processes. Exhibiting both temporal and concentration-dependent characteristics, BCH-HSP-C01 optimally enhances ATG9A translocation within a 72–96 hour window post-administration, achieving an EC50 ~ 5 µM in hiPSC-derived neurons from AP-4-HSP patients. Furthermore, BCH-HSP-C01 markedly increases autophagic flux, as indicated by the elevated levels of LC3-II following its application and restores neuronal phenotypes of adapter protein complex 4 (AP-4)-deficiency.
BCH-HSP-C01, a novel pharmacotherapeutic agent, is engineered to rectify ATG9A-related pathologies. Its primary mode of action entails the regulation of intracellular trafficking mechanisms, with a pronounced effect on the RAB protein family, integral to vesicular transport processes. Exhibiting both temporal and concentration-dependent characteristics, BCH-HSP-C01 optimally enhances ATG9A translocation within a 72–96 hour window post-administration, achieving an EC50 ~ 5 µM in hiPSC-derived neurons from AP-4-HSP patients. Furthermore, BCH-HSP-C01 markedly increases autophagic flux, as indicated by the elevated levels of LC3-II following its application and restores neuronal phenotypes of adapter protein complex 4 (AP-4)-deficiency.
法规信息
新产品
此项目有
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持